169 related articles for article (PubMed ID: 7508886)
1. Association of p53 immunoreactivity with high gleason tumor grade in prostatic adenocarcinoma.
Kallakury BV; Figge J; Ross JS; Fisher HA; Figge HL; Jennings TA
Hum Pathol; 1994 Jan; 25(1):92-7. PubMed ID: 7508886
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate carcinoma.
Petrescu A; Mârzan L; Codreanu O; Niculescu L
Rom J Morphol Embryol; 2006; 47(2):143-6. PubMed ID: 17106522
[TBL] [Abstract][Full Text] [Related]
3. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study.
Sasor A; Wagrowska-Danilewicz M; Danilewicz M
Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
5. Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma.
Iczkowski KA; Pantazis CG; McGregor DH; Wu Y; Tawfik OW
Cancer; 2002 Dec; 95(12):2487-93. PubMed ID: 12467061
[TBL] [Abstract][Full Text] [Related]
6. p53 immunoreactivity in primary and metastatic prostatic adenocarcinoma.
Hughes JH; Cohen MB; Robinson RA
Mod Pathol; 1995 Jun; 8(5):462-6. PubMed ID: 7675761
[TBL] [Abstract][Full Text] [Related]
7. SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.
Pierconti F; Martini M; Cenci T; Petrone GL; Ricci R; Sacco E; Bassi PF; Larocca LM
Prostate; 2017 May; 77(6):597-603. PubMed ID: 28144985
[TBL] [Abstract][Full Text] [Related]
8. Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8 kb major breakpoint region or with p53 protein accumulation.
Kallakury BV; Figge J; Leibovich B; Hwang J; Rifkin M; Kaufman R; Figge HL; Nazeer T; Ross JS
Mod Pathol; 1996 Jan; 9(1):41-7. PubMed ID: 8821955
[TBL] [Abstract][Full Text] [Related]
9. Relationship between apoptosis regulator proteins (bcl-2 and p53) and Gleason score in prostate cancer.
Karaburun Paker S; Kilicarslan B; Ciftcioglu AM; Oztekin S; Sargin FC; Erdogru T; Baykara M
Pathol Oncol Res; 2001; 7(3):209-12. PubMed ID: 11692148
[TBL] [Abstract][Full Text] [Related]
10. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.
Zhao J; Epstein JI
Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862
[TBL] [Abstract][Full Text] [Related]
11. p53 and p21/WAF-1 overexpressions in prostatic adenocarcinoma.
Wan Muhaizan WM; Ahmad PK; Phang KS; Arni T
Malays J Pathol; 2006 Dec; 28(2):93-9. PubMed ID: 18376798
[TBL] [Abstract][Full Text] [Related]
12. Nuclear p53 overexpression in bladder, prostate, and renal carcinomas.
Sinik Z; Alkibay T; Ataoglu O; Biri H; Sözen S; Deniz N; Karaoglan U; Bozkirli I
Int J Urol; 1997 Nov; 4(6):546-51. PubMed ID: 9477181
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 34betaE12 and P63 in 100 consecutive prostate carcinoma diagnosed by needle biopsies.
Wu HH; Lapkus O; Corbin M
Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):285-9. PubMed ID: 15536326
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate.
Zeng L; Rowland RG; Lele SM; Kyprianou N
Hum Pathol; 2004 Mar; 35(3):290-7. PubMed ID: 15017584
[TBL] [Abstract][Full Text] [Related]
15. Correlation between histological type and immunohistochemical profile of prostate cancer and gleason scale gradation.
Iemelynova AA; Grygorenko VM; Cheremuha SV; Romanenko AM
Exp Oncol; 2009 Dec; 31(4):246-9. PubMed ID: 20010526
[TBL] [Abstract][Full Text] [Related]
16. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells.
De Marzo AM; Meeker AK; Epstein JI; Coffey DS
Am J Pathol; 1998 Sep; 153(3):911-9. PubMed ID: 9736039
[TBL] [Abstract][Full Text] [Related]
17. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia.
Jack GS; Brash AR; Olson SJ; Manning S; Coffey CS; Smith JA; Shappell SB
Hum Pathol; 2000 Sep; 31(9):1146-54. PubMed ID: 11014584
[TBL] [Abstract][Full Text] [Related]
18. Evidence of surfactant protein A and D expression decrement and their localizations in human prostate adenocarcinomas.
Kankavi O; Baykara M; Eren Karanis MI; Bassorgun CI; Ergin H; Ciftcioglu MA
Ren Fail; 2014 Mar; 36(2):258-65. PubMed ID: 24168624
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate.
Arora R; Koch MO; Eble JN; Ulbright TM; Li L; Cheng L
Cancer; 2004 Jun; 100(11):2362-6. PubMed ID: 15160339
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of p53 and expression of CD44 in human prostatic cancer and benign prostatic hyperplasia: an immunohistochemical study.
Zhang XH; Sakamoto H; Takenaka I
Br J Urol; 1996 Mar; 77(3):441-4. PubMed ID: 8814853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
